Trials / Unknown
UnknownNCT04854681
Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TQB2928 Injection in Patients With Advanced Solid Tumors or Hematological Malignancies
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα and enhances the phagocytosis of cancer cells by macrophages. In preclinical in vivo models, TQB2928 was active against a wide range of solid tumors and hematologic malignancies. This is the first-in-human phase 1 trial of TQB2928 in patients with advanced solid tumors and hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2928 Injection | 4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal. |
Timeline
- Start date
- 2021-08-01
- Primary completion
- 2022-07-01
- Completion
- 2022-12-01
- First posted
- 2021-04-22
- Last updated
- 2021-04-22
Source: ClinicalTrials.gov record NCT04854681. Inclusion in this directory is not an endorsement.